# Functional evidence for a sequence variant

Source: https://onco.cc/terms/functional-variant-evidence/  
OnCo record `functional-variant-evidence` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A functional assay tests what a genetic change does in a particular system. The result needs to fit the question about disease, and it does not automatically identify a useful treatment.

## Summary

ClinGen's primary recommendations for functional variant evidence evaluate disease mechanism, assay relevance, assay validation and the evidence for an individual variant. An abnormal assay result needs controls and evidence that the measured function is relevant to the disease mechanism. The PS3/BS3 framework concerns sequence-variant interpretation; it is not a cancer-drug actionability score. Treatment claims require evidence for the exact alteration, disease and intervention context.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: variant functional assay evidence; PS3 and BS3 functional evidence

## Sources

- ClinGen functional-evidence recommendations (2019): https://doi.org/10.1186/s13073-019-0690-2
- Clinical actionability framework (2018): https://doi.org/10.1093/annonc/mdy263

## Connected records

- terms: [Actionable genomic biomarkers](https://onco.cc/terms/cancer-drivers-vs-actionable/), [Drug target engagement](https://onco.cc/terms/drug-target-engagement/), [Evidence from measurement to patient benefit](https://onco.cc/terms/measurement-to-benefit-evidence/), [On-target validation of drug effects](https://onco.cc/terms/on-target-drug-validation/), [Variant of uncertain significance (VUS)](https://onco.cc/terms/vus/)

---
JSON: https://onco.cc/api/v1/entities/functional-variant-evidence.json